RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Trial details
- Registry ID
- NCT06154252
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Rese-cel; Resecabtagene autoleucel
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyNCT06154252 | Cabaletta Bio | Phase 2, Phase 3 | Recruiting | 2028-07Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |